Table 3.
MedDRA preferred term | Patients with malignant lymphoma (N = 51) | |
---|---|---|
All grades | Grade 3 or 4 | |
Any TEAE | 51 (100.0) | 51 (100.0) |
TEAEs occurring in ≥ 10% of patients | ||
Febrile neutropenia | 49 (96.1) | 49 (96.1) |
Diarrhea | 42 (82.4) | 6 (11.8) |
Stomatitis | 32 (62.7) | 13 (25.5) |
Nausea | 29 (56.9)) | 4 (7.8) |
Decreased appetite | 28 (54.9) | 16 (31.4) |
Malaise | 24 (47.1) | 0 |
Dysgeusia | 19 (37.3) | 0 |
Hepatic function abnormal | 17 (33.3) | 5 (9.8) |
Vomiting | 15 (29.4) | 1 (2.0) |
Hypokalemia | 12 (23.5) | 3 (5.9) |
Oropharyngeal pain | 12 (23.5) | 3 (5.9) |
Pharyngitis | 12 (23.5) | 3 (5.9) |
Pyrexia | 11 (21.6) | 0 |
Hypersensitivity | 10 (19.6) | 1 (2.0) |
Dermatitis contact | 9 (17.6) | 0 |
Insomnia | 9 (17.6) | 0 |
Proctalgia | 9 (17.6) | 0 |
Rash | 7 (13.7) | 0 |
Headache | 6 (11.8) | 0 |
No grade 5 events were reported. Number of patients (%) are shown
MedDRA Medical Dictionary for Regulatory Activities, TEAE treatment-emergent adverse event